转移性结直肠癌维持治疗策略:随机临床试验的系统评价与网络Meta分析
结果显示维持治疗较观察显著改善无进展生存(HR 0.58,95%CI 0.43-0.77)但未改善总生存(HR 0.91,95%CI 0.83-1.01);持续全量化疗至进展对比观察在PFS和OS均无获益。作者推荐以氟嘧啶为基础(联合或不联合贝伐珠单抗)的维持策略,但鉴于OS获益不明确,观察仍可作为可接受的替代选择。
要点
- 持续全量诱导化疗至进展对比观察无PFS或OS获益(PFS HR 0.71,95%CI 0.46-1.09;OS HR 0.95,95%CI 0.85-1.07)。
- 维持治疗对比观察显著改善PFS(HR 0.58,95%CI 0.43-0.77),但OS无显著获益(HR 0.91,95%CI 0.83-1.01)。
- 氟嘧啶联合贝伐珠单抗的PFS SUCRA概率最高(99.8%),氟嘧啶单药OS SUCRA概率最高(81.3%)。
核心结论
- 对于转移性结直肠癌患者,持续全量诱导方案至进展无获益,应引入观察或维持治疗阶段。
- 首选以氟嘧啶为基础、联合或不联合贝伐珠单抗的维持策略。
- 鉴于OS获益不明确,共同决策时应将观察列为可接受的替代选择。
研究设计与样本
- 系统评价与网络Meta分析,检索MEDLINE、Embase、Scopus、Web of Science及Cochrane CENTRAL。
- 采用DerSimonian and Laird随机效应模型合并效应,网络Meta分析使用随机效应一致性模型,并以SUCRA概率排序。
主要发现
- 持续全量细胞毒化疗至进展对比观察:PFS HR 0.71(95%CI 0.46-1.09),OS HR 0.95(95%CI 0.85-1.07)。
- 维持治疗对比观察:PFS HR 0.58(95%CI 0.43-0.77),OS HR 0.91(95%CI 0.83-1.01)。
- 所有维持策略(氟嘧啶、氟嘧啶+贝伐珠单抗、贝伐珠单抗)对比观察均显著改善PFS。
- SUCRA分析中PFS概率:氟嘧啶67.1%、氟嘧啶+贝伐珠单抗99.8%、贝伐珠单抗36.5%;OS概率:氟嘧啶81.3%、氟嘧啶+贝伐珠单抗73.2%、贝伐珠单抗32.6%。
临床怎么用
- 对完成诱导化疗的转移性结直肠癌患者,不应继续全量诱导方案至进展,应转换为维持治疗或观察。
- 维持治疗优先选择氟嘧啶联合或不联合贝伐珠单抗,贝伐珠单抗单药维持的PFS和OS排序概率较低。
- 与患者共同决策时需告知维持治疗改善PFS但OS获益不明确,观察为可接受的替代方案。
局限性
- 原文未报告纳入试验间具体异质性指标及一致性假设检验结果。
- 原文未报告各维持策略亚组(如分子分型、原发灶部位)的疗效差异。
- 原文未报告维持治疗相关不良事件或生活质量数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In metastatic colorectal cancer, induction combination chemotherapy with a targeted agent is considered the mainstay of treatment. Multiple randomized clinical trials have examined different strategies of continuing cytotoxic therapy until progression compared with a period of either observation or the use of various maintenance agents. However, those randomized clinical trials have shown inconsistent efficacy results that make it challenging to draw any conclusion on which strategy is preferred. Therefore, a network meta-analysis is helpful to compare different agents across randomized clinical trials. OBJECTIVE: To evaluate the comparative effectiveness of different treatment strategies for patients with metastatic colorectal cancer. EVIDENCE REVIEW: MEDLINE, Embase, Scopus, Web of Science, and the Cochrane Central Register of Controlled Trials were searched for randomized clinical trials evaluating different strategies for patients with previously untreated metastatic colorectal cancer. Trials of interest included those including patients with metastatic colorectal cancer who were treated with an initial period of cytotoxic chemotherapy (with or without a biologic) and then switched to one of the following strategies: observation; maintenance with bevacizumab (Bev), fluoropyrimidine (FP), or both (FP + Bev); or continuing the induction regimen until progression. Outcomes of interest included overall survival (OS) and progression-free survival (PFS). The overall effect was pooled using the DerSimonian and Laird random-effects model. Network meta-analysis was conducted using a random-effects consistency model to pool evidence from direct and indirect comparisons. Agents were ranked using surface under the cumulative ranking (SUCRA) probabilities. Higher SUCRA scores correspond to greater efficacy. Initial analysis was performed on December 18, 2018. An updated search was performed in April 2019, and no additional studies were added. FINDINGS: Twelve trials at low risk of bias (5540 patients; age range, 23-85 years; 64.4 % male) were included. Network meta-analysis showed no benefit of continuing full cytotoxic chemotherapy until progression vs observation in terms of PFS (hazard ratio, 0.71; 95% CI, 0.46-1.09) and OS (hazard ratio, 0.95; 95% CI, 0.85-1.07). Compared with observation, maintenance therapy showed a PFS benefit (hazard ratio, 0.58; 95% CI, 0.43-0.77) but not an OS benefit (hazard ratio, 0.91; 95% CI, 0.83-1.01). All maintenance strategies (FP, FP + Bev, and Bev) showed significant improvement in PFS vs observation. On SUCRA analysis, maintenance treatment (FP or FP + Bev) had the highest likelihood of achieving improved PFS (67.1% for FP, 99.8% for FP + Bev, and 36.5% for Bev) and OS (81.3% for FP, 73.2% for FP + Bev, and 32.6% for Bev). CONCLUSIONS AND RELEVANCE: For patients with metastatic colorectal cancer, there is no benefit to continuing the full induction regimen until progression, without a period of either observation or maintenance treatment. A maintenance strategy with a fluoropyrimidine, with or without the addition of bevacizumab, is preferred. However, given the lack of a clear OS benefit, shared decision-making should include observation as an acceptable alternative.
引用
- Sonbol MB, Mountjoy LJ, Firwana B, et al. The Role of Maintenance Strategies in Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis of Randomized Clinical Trials. JAMA Oncol. 2020. PMID: 31855256. doi:10.1001/jamaoncol.2019.4489
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。